Health & Fitness
Wed, March 28, 2012
SAN DIEGO--([ BUSINESS WIRE ])--Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T. Proehl, president and chief executive officer, will make a presentation at the 11th Annual Needham Healthcare Conference on Wednesday, April 4, 2012, at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) at the New York Palace Hotel in New York City.
A webcast of the presentation will be available during the event at [ www.santarus.com ] and will be archived and available on the website for 14 days.
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The companyas current commercial efforts are focused on [ GLUMETZA ] (metformin hydrochloride extended release tablets) and [ CYCLOSET ] (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on [ FENOGLIDE ] (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol.
Santarus has a diverse product development pipeline. A New Drug Application for UCERISa" (budesonide) tablets for induction of remission of mild to moderate active ulcerative colitis is under review by the U.S. Food and Drug Administration with a response expected in October 2012. The pipeline also includes two late-stage investigational drugs: RHUCIN (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX for treatment of travelersa diarrhea, both of which are being evaluated in Phase III clinical studies. In addition, the companyas investigational monoclonal antibody, SAN-300, is being evaluated in a Phase I clinical program. More information about Santarus is available at [ www.santarus.com ].
Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarusa business, including, without limitation: difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarusa products; and other risks detailed in Santarusa prior press releases as well as in public periodic filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.All forward-looking statements are qualified in their entirety by this cautionary statement and Santarus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Santarus, FENOGLIDE and UCERISa" are trademarks of Santarus, Inc.GLUMETZA is a trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc.CYCLOSET is a trademark of VeroScience LLC.MMX is a trademark of Cosmo Technologies Limited. RHUCIN is a trademark of Pharming Group NV.
